Cytokinetics, Incorporated
CYTK
$39.48
$0.330.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.56% | -12.02% | -5.66% | 0.92% | -5.77% |
| Total Depreciation and Amortization | -1.16% | 0.21% | 3.22% | -63.20% | 241.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.68% | 46.86% | 7.88% | 153.38% | -61.03% |
| Change in Net Operating Assets | 322.04% | 1.20% | 138.00% | -157.27% | 2,930.32% |
| Cash from Operations | 35.40% | -2.20% | 23.31% | -74.92% | 23.04% |
| Capital Expenditure | -84.02% | 63.39% | -- | -- | 65.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 352.87% | 93.17% | -2,090.24% | 140.13% | -211.02% |
| Cash from Investing | 346.07% | 93.09% | -2,096.10% | 140.09% | -211.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.69% | -0.56% | -208.80% | -319.82% | -2.30% |
| Issuance of Common Stock | 2.55% | -98.99% | 406.52% | -27.13% | 3,710.23% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -100.00% |
| Cash from Financing | -30.39% | -99.58% | 691.02% | -38.51% | 211.33% |
| Foreign Exchange rate Adjustments | 331.75% | -887.50% | -40.74% | 235.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.49% | -304.16% | 909.29% | -47.85% | -57.07% |